Ubs Group Ag Nektar Therapeutics Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Nektar Therapeutics stock. As of the latest transaction made, Ubs Group Ag holds 112,521 shares of NKTR stock, worth $104,644. This represents 0.0% of its overall portfolio holdings.

Number of Shares

112,521

Previous 57,513 95.64%

Holding current value

$104,644

Previous $71,000 105.63%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.11 - $1.48 $61,058 - $81,411	55,008 Added 95.64%	112,521 $146,000
Q2 2024 Aug 13, 2024	BUY	$0.9 - $1.83 $48,887 - $99,403	54,319 Added 1700.66%	57,513 $71,000
Q1 2024 May 13, 2024	SELL	$0.49 - $0.96 $118,945 - $233,036	-242,746 Reduced 98.7%	3,194 $2,000
Q4 2023 Feb 09, 2024	BUY	$0.42 - $0.57 $82,758 - $112,314	197,043 Added 402.98%	245,940 $137,000
Q3 2023 Nov 09, 2023	BUY	$0.51 - $1.05 $19,910 - $40,993	39,041 Added 396.11%	48,897 $29,000
Q2 2023 Aug 11, 2023	SELL	$0.53 - $1.03 $610 - $1,185	-1,151 Reduced 10.46%	9,856 $5,000
Q1 2023 May 12, 2023	SELL	$0.64 - $3.15 $256 - $1,260	-400 Reduced 3.51%	11,007 $7,000
Q4 2022 Feb 08, 2023	SELL	$2.03 - $4.28 $6,954 - $14,663	-3,426 Reduced 23.1%	11,407 $25,000
Q3 2022 Nov 10, 2022	BUY	$3.04 - $5.14 $7,283 - $12,315	2,396 Added 19.27%	14,833 $48,000
Q2 2022 Aug 10, 2022	SELL	$3.17 - $6.17 $19,619 - $38,186	-6,189 Reduced 33.23%	12,437 $47,000
Q1 2022 May 16, 2022	SELL	$4.16 - $13.72 $4,625 - $15,256	-1,112 Reduced 5.63%	18,626 $101,000
Q4 2021 Feb 14, 2022	SELL	$10.83 - $18.41 $125,238 - $212,893	-11,564 Reduced 36.94%	19,738 $267,000
Q3 2021 Nov 15, 2021	SELL	$13.07 - $18.84 $1.47 Million - $2.12 Million	-112,417 Reduced 78.22%	31,302 $562,000
Q2 2021 Aug 13, 2021	BUY	$16.52 - $20.4 $923,385 - $1.14 Million	55,895 Added 63.64%	143,719 $2.47 Million
Q1 2021 May 12, 2021	SELL	$16.56 - $25.46 $590,231 - $907,445	-35,642 Reduced 28.87%	87,824 $1.76 Million
Q4 2020 Feb 11, 2021	BUY	$15.77 - $19.03 $8,074 - $9,743	512 Added 0.42%	123,466 $2.1 Million
Q3 2020 Nov 12, 2020	BUY	$16.59 - $24.79 $1.57 Million - $2.34 Million	94,542 Added 332.75%	122,954 $2.04 Million
Q2 2020 Jul 31, 2020	SELL	$16.86 - $23.44 $941,445 - $1.31 Million	-55,839 Reduced 66.28%	28,412 $658,000
Q1 2020 May 01, 2020	SELL	$14.47 - $27.96 $2.4 Million - $4.64 Million	-165,877 Reduced 66.32%	84,251 $1.5 Million
Q4 2019 Feb 14, 2020	BUY	$15.87 - $23.12 $1.09 Million - $1.59 Million	68,771 Added 37.92%	250,128 $5.4 Million
Q3 2019 Nov 14, 2019	BUY	$16.91 - $36.27 $1.6 Million - $3.44 Million	94,734 Added 109.36%	181,357 $3.3 Million
Q2 2019 Aug 14, 2019	SELL	$31.0 - $36.3 $263,903 - $309,021	-8,513 Reduced 8.95%	86,623 $3.08 Million
Q1 2019 May 14, 2019	BUY	$31.58 - $46.35 $925,736 - $1.36 Million	29,314 Added 44.54%	95,136 $3.2 Million
Q4 2018 Feb 14, 2019	SELL	$30.43 - $56.65 $1.37 Million - $2.55 Million	-45,005 Reduced 40.61%	65,822 $2.16 Million
Q3 2018 Nov 14, 2018	BUY	$46.46 - $68.49 $756,229 - $1.11 Million	16,277 Added 17.22%	110,827 $6.76 Million
Q2 2018 Aug 14, 2018	SELL	$46.25 - $104.45 $4.08 Million - $9.21 Million	-88,199 Reduced 48.26%	94,550 $4.62 Million
Q1 2018 May 15, 2018	BUY	$57.4 - $108.44 $8.59 Million - $16.2 Million	149,581 Added 450.98%	182,749 $19.4 Million
Q4 2017 Feb 14, 2018	SELL	$23.02 - $60.5 $68,369 - $179,685	-2,970 Reduced 8.22%	33,168 $1.98 Million
Q3 2017 Nov 14, 2017	SELL	$17.79 - $24.0 $229,046 - $309,000	-12,875 Reduced 26.27%	36,138 $867,000
Q2 2017 Aug 14, 2017	BUY	N/A	24,033 Added 96.21%	49,013 $958,000
Q1 2017 Nov 14, 2017	BUY	N/A	24,980	24,980 $586,000

Others Institutions Holding NKTR

# of Institutions

145

Shares Held

139M

Call Options Held

32.6K

Put Options Held

14.1K

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account